| |
The number of blockbusters continues to increase. The number is set
to increase to 112 in 2007. Of the products set to receive FDA approval
this year and generate blockbuster status on an annual basis, GSK's
Cervarix, intended for the prevention of infection and lesions from the
two cancer-causing types of HPVs holds great potential. |
|
| |
With 4 drugs now in the marketplace (a 100% rise from 2 years ago),
the cannabinoid market continues to grow. Attitudes to the drugs are
changing ensuring greater market penetration, and the first cannabinoid
blockbuster is now a certainty. |
|
| |
AMD is the most common cause of vision loss in the developed world
for those over 50 years of age. We estimate there are over 20 million
cases in the US and Europe. Dry AMD accounts for 90% of cases and has no
suitable cure. Wet AMD drug sales will soon see the first blockbuster.
Novartis achieved first to market success with their Visudyne drug in
1999. However work from Pfizer selling Macugen and Lucentis from
Genentech have seen it sales reduced. These drugs are refered to in the
press as ‘miracle drugs’ – saving sight for millions. But issues over
prescribing still remain. |
|
| |
In a market believed to approach 5 million people in the leading
pharma markets, the market for rheumatic anti-inflammatory drugs is both
profitable and set to increase due to new launches. The annual revenue
to Q3 2006, from the main prescription anti-inflammatory drugs
worldwide, including non steroidal anti-inflammatories (NSAIDs),
anti-rheumatic corticosteroid combinations and specific anti-rheumatics
was in the order of $16bn worldwide. This market cannot be ignored. A
life-long disease with no cure, the disease has been targeted greatly by
pharma companies with the launch of novel targetted biologic therapies.
However this has meant that the market for severe RA has become crowded
- but is it saturated? |
|
| |
* * * Latest totally updated market focussed report, available now *
* *
Over 160+ pages dedicated to tissue engineering and stem cell
analysis.
The market potential of this technology is so huge that revenues may be
in excess of $10 billion by 2013. This is a market that you should be
part of - NOW!! With a complex regulatory structure still to overcome,
yet continued high level investment, many of your competitors are aware
of the the commercial opportunities within Tissue Engineering & Stem
Cell Technology. |
|
| |
With headquarters in Basel, Switzerland, Novartis is recognised as
being one of the strongest performing pharmaceutical companies in terms
of sales, high revenue growth, acquisitions, breadth of portfolio,
product launches and pipeline developments. In 2006 - ten years after
its inception - Novartis generated total net sales of $37bn worldwide. |
|
| |
The two major problems for biotech drugs are their mode of delivery
and relative instability. The majority of delivery methods for
biological drugs involve injection, which is not necessarily ideal for
most indications. As the biotech sector starts to heat up, the industry
has started to look for new ways of delivering these highly successful
drugs. |
|
| |
'The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012'
is a new report from visiongain providing analysis of the current and
future market for IBD drugs across all major indications. Forecasts are
given based on new product launches, upcoming patent expiry dates, and
ongoing clinical trials to enable you to predict changes in the dynamics
of the global IBD market. Autoimmune disease is a multimillion dollar
market set to increase as world prevalence rates rise and the population
lives longer. Inflammatory bowel disease (IBD) affect millions of people
worldwide with 2.8 million currently diagnosed with ulcerative colitis (UC)
or Crohn’s disease (CD) in the US alone. The incidence of IBD is rising
in developing countries around the world. Currently the global market is
estimated at $16bn and this is set to continue to rise. |
|
| |
Key questions remain over theranostics. How can your company secure
key successes and ideals in personalized medicine - aiming the right
drug at the right person and at the right time. Plus with increased FDA
regulation, how can we guarantee that that specific drug is safe for
that individual. These issues are not going away, but one report can
make it alot easier for you and your company. |
|
| |
Stem cells are without doubt the most controversial area of science
at the moment. The world markets have latched onto the potential offered
by stem cells to modern medicine and, as a result, the research is in
the public eye on an almost daily basis. Are you fully informed of the
market potential of stem cell work? Do you know which companies and
research organisations you must work with now? This report tells you.
So what is all the controversy about? And what products are we likely
to see, in what areas and when, if stem cell work continues at pace?
|
|
| |
"Lung cancer vaccine to be tested" "New US bill requires cancer
vaccine for girls" "Cancer vaccine too expensive".
These are just some of the news headlines that have seen the world
cancer vaccine market turned on its head. The benefits are
unquestionable, the costs of the drugs however may yet see take-up slow.
How will this effect your company? This report will tell you.
There are two types of cancer vaccines:
> Prophylactic cancer vaccines, designed to prevent the development
of cancer, they are given to healthy subjects to prevent infection with
cancer-causing viruses
> Therapeutic cancer vaccines, designed to treat existing cancers, they
are given to cancer patients to stimulate the immune system into
recognising and destroying their existing cancer |
|
| |
The purpose of visiongain’s Developing Markets Series is to examine
prospects for the growth of pharmaceutical revenues in the developing
economies of Asia, Latin America and Eastern/Central Europe in three
linked reports. Central and Eastern European (CEE) Developing Markets
for Pharmaceuticals, 2006-2011 – Part 3 of Developing Markets -
discusses prospects for the large developing market of Central and
Eastern Europe. The other reports discuss Asia and Latin America
respectively. Importantly, the growth of pharmaceutical markets in
economically developing nations has the potential to offset serious
problems currently being experienced by the global industry. The purpose
of this visiongain report is to examine the prospects for the growth of
pharmaceutical revenues in the developing economies of Central and
Eastern Europe, at both regional and national level. |
|
| |
The monoclonal market is set to expand dramatically. Ten years ago
there were only two monoclonal antibody drugs on the world market, now
there are nineteen FDA approved therapies – including six blockbuster
drugs. The market in 2005 was worth over $13bn, worldwide, representing
an astounding growth of 37% - can you believe it? Well you should and to
make sure you capture an increased share of this growth order this
report NOW. Biotech pipelines are overflowing with over 160 monoclonal
antibody based drugs; the market is thriving!
Will the current monoclonal blockbusters continue to grow? What are
the hottest projects in the pipeline? What will restrain the market in
the future? These are questions you need to know the answers to. |
|
| |
The purpose of visiongain’s Developing Markets Series is to examine
the prospects for the growth of pharmaceutical revenues in the
developing economies of Asia, Latin America and Eastern/Central Europe.
Latin American Developing Markets for Pharmaceuticals, 2006-2011
discusses prospects for the large developing market of Latin America.
Importantly, the growth of pharmaceutical markets in Latin America has
the potential to offset serious problems currently being experienced by
your industry. The purpose of this visiongain report is to examine the
prospects for the growth of pharmaceutical revenues in the developing
economies of Latin America, at both regional and national level. |
|
| |
Will the economic growth in new Asian markets allow you to offset
global problems? With the Japan market slow and stagnant what other
countries in the region offer you the greatest opportunities and how can
you succeed in them. This report tells you.
Asian Developing Markets for Pharmaceuticals, 2006-2011 delivers to
you unique prospects for the largest developing pharmaceutical market -
Asia.
This report predicts that all the leading developing markets will
exhibit strong growth from 2006-2011. Rapid economic growth and large,
under-served populations will drive that expansion in pharmaceutical
revenues. There will be significant growth in sales of both branded and
generic drugs through increasing demand from both public and private
healthcare sectors.
|
|
| |
"Outsourcing defines future of Euro Bioinformatics market"
"Jump on bioinformatics bandwagon"
These are just two newspaper headlines that appeared today. Managing
your data is critical to your organisation. You already know that. But
is your company doing it as effectively as it should? Find out by
reading this brand new report.
This report delivers answers on how you can benefit from the
commercial prospects of bioinformatics, now. The ultimate goal of
bioinformatics is to uncover the wealth of biological information hidden
in the mass of data, to obtain a clearer insight into the fundamental
biology of organisms. Is your Bioinformatic strategy working to the
maximum level. These recent developments have a profound relevance to
pharmaceutical development.
|
|
| |
More money is spent advertising alcohol than any other product. For
some, it like gambling and cigerettes are pleasant distractions, yet for
others they are the generators of unbearable cravings and the cause of
considerable distress. For them their addition is a disease. According
to a new report by visiongain - Anti-addiction Therapies, 2006-2011 -
society is crying out for solutions. Which pharmaceutical companies are
now aiming to be that cure? This report will tell you. |
|
| |
The number of people suffering from some sort of allergy is on the
rise and the demand for reliable treatments for allergic rhinitis and
other allergic conditions is on the rise worldwide. The market is a
mature one with a number of high profile patent losses in the near
future and a strong OTC segment. Will there be a replacement for Zyrtec
or Allegra in the near Future? What role will the new improved vaccines
play in the next five years? Read visiongain’s new report to find out.
|
|
 |
In stark contrast to the rest of the pharmaceutical industry, the
world market for biotech drugs is thriving. In 2005, biotech revenues
reached $60bn and visiongain predicts that this will continue - YOU MUST
BE PART OF THIS SUCCESS NOW. Having grown 16.5 per cent from 2004's
revenues, double-digit growth of the market will continue to the end of
the decade. You need to be aware of how you can succeed in this area. 1
report will tell you all you need to know.
- Over 250+ pages
- Over 150 tables and figures
- Global revenues & growth rates for the leading biotech drugs
- Company profiles of the leading biotech firms
- A comprehensive analysis of the global market, 2005-2011
- Revenue forecasts for the leading biotech drugs
- Revenues into therapeutic area
- Pipeline treatments
- A geographic breakdown of the market
- A Focus on biogenerics |
|
| |
The purpose of this visiongain report is to examine the prospects
for the growth of pharmaceutical revenues in the developing economies of
Asia, Latin America and Eastern/Central Europe at both regional and
national level. The growth of pharmaceutical markets in the developing
nations has the potential to offset serious problems currently
experienced by the global industry. The principal challenge is slow
growth in North America, Western Europe and Japan.
|
|
| |
The asthma treatment market is a $15 billion market, driven by an
increasing prevalence and yet without a treatment to cure this
debilitating disease. All current drugs treat the symptoms but not the
underlying cause. It is currently dominated by GSK with its $5.5 billion
blockbuster, Advair/Seretide. However, this combination treatment is
about to have its first real competition with Symbicort approved for the
US market in July 2006. Combination drugs appear likely to dominate the
mid-term forecast period as assessed by visiongain. |
|
| |
The Contract Pharma market in 2005 was worth an estimated $57bn.
Attitudes within the pharmaceutical industry are slowly changing and the
use of strategic outsourcing is becoming an accepted practice.
Specialised technologies and a global presence are becoming more
important for a greater number of pharmaceutical companies. Even big
pharma is increasingly using outsourcing to spread the risk of
development and lower fixed costs.
|
|
| |
The purpose of this visiongain report is to examine the commercial
prospects of online technologies in the pharmaceutical sector. In
particular, this report examines the fast-growing fields of
pharmaceutical eMarketing, eDetailing, ePrescribing and online drug
sales. Online technological solutions have great potential to benefit -
even revolutionise – the marketing efforts of drug companies. Visiongain
predicts that all aspects of pharmaceutical eMarketing will exhibit
steady growth from 2006-2011. Key technological solutions - such as
Internet-enabled DTC promotion, eDetailing and ePrescribing - will drive
that expansion. Sales of prescription drugs via the Internet will also
be significant. |
|
| |
At present ADRs are the sixth largest cause of death in the US. Drug
safety is a huge issue facing the industry today and the risk is high
with the possible loss of a key revenue producing drug coupled with
potentially damaging litigation. The financial risk facing Merck on the
withdrawal of Vioxx was considerably beyond the loss of its $2.5 bn
yearly revenues.
|
|
| |
The purpose of this visiongain report is to examine the commercial
prospects of nanotechnology in medicine – the fast-developing and
increasingly lucrative field of nanomedicine. Nanotechnology has great
potential to benefit - even revolutionise - the pharmaceutical, medical
devices, diagnostics and imaging sectors. Visiongain predicts that
nanomedicine will exhibit strong growth in all sectors from 2006-2011,
leading to multi-billion dollar revenues. Key technology platforms such
as nanocrystals, nanotubes, dendrimers, fullerenes, quantum dots and
molecular scaffolding will drive that market expansion. |
|
| |
The world biogenerics market is about to develop on a very large
scale. The approval of generic growth hormones in the US and Europe has
finally occurred and this has created a new source of revenue for
generic companies. After years of indecision and false starts, it
appears that generic biotech drugs are going to become available on the
large, lucrative markets of the US and Europe. However, despite the
introduction of Biosimilar guidelines by the EU and a heightening of the
debate within the FDA, key questions for the pharmaceutical industry
still remain concerning this new type of generic drug. The main issue is
the degree to which the new biosimilar but not bioequivalent generic
drugs will have to be tested prior to market launch. The delay in firm
guidance and legislation is concerned almost entirely with this issue. |
|
| |
The Indian pharmaceutical market is the 15th largest individual
market by sales, but the 4th by volume of product. With domestic drug
sales of almost $5 billion, Indian companies have also developed a
considerable service industry for the global pharmaceutical market.
However the Indian pharmaceutical market looks set for considerable
change.
|
|
| |
The global pharmaceutical market with sales of approximately $550
billion is about to enter a pivotal period in its history. The industry
has been used to double digit growth rates but growth has now dropped to
below 10% for the first time. In addition to this whole swathes of
lucrative high revenue earning drugs are going to lose patent.
Ordinarily, the industry would have been able to cope with this after
all patent loss is a normal part of the industrial process. But this
time the industry faces serious problems, pipelines are notoriously
thin. The industry is going to have huge difficulties in replacing those
drugs going off patent and the high levels of revenue that they earn.
The industry is going to have incorporate the new culture of Product
Lifecycle Management (PLM) if it is to salvage some of those lost
revenues. |
|
| |
In sharp contrast to the branded pharmaceutical market, which has
stalled in recent year, the generics market is enjoying a period of
unprecedented success. In 2005 the world generics market was worth
$45bn, a growth of 14% on the previous year. Visiongain expects this
level of growth to continue over the forecast period of this report.
|
|
| |
Diabetes effects approximately 170 million people worldwide and is
increasing, with the WHO predicting 300 million diabetics by 2025. The
US alone has 20.8 million people suffering with diabetes. This equates
to approximately 6% of the population. It was the 6th most common cause
of death as recorded on US death certificates.
|
|
|
|
| |
The purpose of this visiongain report is to examine the prospects of
the world gastrointestinal market. The gastrointestinal (GI) disorders
market is one of the largest and most important in the pharmaceutical
industry, generating revenues of over $16 billion in 2004.
|
|
| |
The Japanese pharmaceutical market is the second largest individual
market and with sales of $60 billion constitutes approximately 11% of
the world market. However, it is a market that frustrates the major
pharmaceutical companies as it is growing at a significantly lower rate
of growth than the average of the world pharmaceutical markets. |
|
| |
In 2004 total world revenues for branded antidepressant drugs was
worth over $13bn, but with only ten drugs on the market. However, nine
out of these ten drugs faces a loss of patent in the period 2006-2010.
Dr Tom Newton, pharmaceutical analyst with visiongain and author of
The World Market for Antidepressants, 2006, predicts that the world
market will crash producing revenues in 2010 of only $7bn. This is a
loss of almost 50% of total revenues. |
|
| |
Generic companies and the drugs they produce are now an important
part of the major pharmaceutical markets. The growth rate in the
industry is increasing, nine of the top ten fastest growing
pharmaceutical companies are generic and the demand for cheaper drugs is
increasing. |
|
| |
The world hypertension market generated over $25 billion in 2004,
with steady growth from the previous year. In this report, visiongain
forecasts that revenues in the world hypertension market will grow to
nearly $30 billion per year by 2010. |
|
| |
Pfizer has just issued a warning on how deep the pharmaceutical
industry's problems have gone. The company has cut its profit
expectations for this year. |
|
| |
The sleep disorder treatment market had sales of $2.03bn in 2004. It
is dominated by one product, Ambien indicated for the short-term
treatment of insomnia and providing Sanofi-Aventis with an 87% market
share. |
|
| |
The schizophrenia world market generated total revenues of nearly
$12 billion in 2004. The market is growing now. Are you capitalising on
this market? |
|
| |
One of the two major issues for a drug company, besides gaining
market authorisation, is persuading the country in question to reimburse
them, that is pay for the drug that the company is attempting to market.
|
|
| |
The biopharmaceutical market has undergone rapid expansion since its
emergence thirty years ago. No longer is the market confined to growth
hormones, insulin and red blood cell stimulating agents.
|
|
| |
The Pharmaceutical Wholesale and Distribution Industry has survived
on continual low profits while the pharmaceutical companies of whom its
serves continues to thrive. The major problem facing the industry today
is how to increase its profitability. |
|
| |
Is the neurodegeneratives disease market growing? Are current drug
therapies valuable? What are the current unmet needs in this market?
What is the future of this market? |
|
| |
Urinary tract agents (UTAs) are simply drugs used to treat disorders
of the urinary tract. They do not treat infections of the urinary tract
(UTIs) as some antibiotics do, but these drugs may provide relief from
the symptoms of a UTI.
|
|
| |
Today, the global endocrine pharmaceutical market is a highly
lucrative multi-billion dollar business, but, can you confidently answer
the following?
|
|
| |
The animal health businesses of the major pharma companies have two
parts: one for food producing animals and one for companion animals such
as dogs and cats. |
|
| |
Anticonvulsant therapies encompass all drugs used primarily to
prevent seizures or control their incidence or severity. These drugs are
however versatile and can be used for a variety of other disorders,
namely bipolar disorder, neuropathic pain and migraine prophylaxis.
|
|
| |
Proteins that are engineered in the laboratory for pharmaceutical
use are known as therapeutic proteins. The majority of
biopharmaceuticals marketed to date are recombinant therapeutic protein
drugs.
|
|
| |
Today's cannabinoid market is undergoing rapid expansion. Currently
just two products are available on this controversial market: Marinol
from Unimed Pharmaceuticals and Nabilone marketed by Cambridge
Laboratories. Both indicated for the control of chemotherapy- induced
nausea and vomiting, Marinol has additional approval as an appetite
stimulant to treat anorexia assocaited with HIV/AIDS.
|
|
| |
Pharmacoeconomics is the branch of economics that applies
cost-benefit, cost-effectiveness, cost-minimisation, and cost-utility
analyses to compare the economics of different pharmaceutical products
or to compare drug therapy to other treatments. |
|
